Whole Blood Volume-Based Absolute Quantification of HTLV-1 Proviral Load: A Comparative Method Evaluation Study Authors: Gabriel O. Franco, Andreas Stocker, Eduardo M. Netto, Heliene Pereira, Carlos Brites Published: 2026 ABSTRACT The proviral load of human T-cell lymphotropic virus type 1 (HTLV-1) is an important biomarker associated with the monitoring and risk stratification of adult T-cell leukemia/lymphoma (ATL) and HTLV-1-associated myelopathy/tropical spastic paraparesis (HAM/TSP). However, the lack of standardized quantification methods limits its broader application. This study evaluated a novel absolute quantification approach based on whole blood volume and compared its performance with established protocols. A total of 66 HTLV-1-infected individuals were analyzed using six qPCR-based methodologies, including volumetric quantification (copies/µL) by absolute quantification and the Tamegão-Lopes method, as well as normalization per 1000 cells (whole blood, buffy coat, PBMCs, and CD4+ T cells). Association and agreement were assessed using Pearson’s correlation, Bland–Altman analysis, concordance correlation coefficients (CCCs), and Deming regression. Absolute quantification showed strong correlation with both the Tamegão-Lopes method and CD4+-based quantification (r = 0.93 and 0.84, respectively; p < 0.001) and high agreement (CCC = 0.866 and 0.811, respectively), with modest systematic bias (−0.273 log10 copies/µL and 0.115 log10 copies/103 cells, respectively). Leukocyte-normalized methods showed greater discrepancies, likely due to dilution by uninfected cells. These findings show that quantification based on total blood volume is a simplified, operationally feasible alternative for assessing HTLV-1 proviral load. 1. Introduction The human T-cell lymphotropic virus type 1 (HTLV-1) was the first identified human retrovirus and was isolated from lymphocytes of a patient with cutaneous lymphoma [1]. HTLV-1 has a wide global distribution, and current estimates suggest that between 5 and 10 million people worldwide are living with HTLV-1 infection. Most (around 90%) of these individuals remain asymptomatic throughout their life, which complicates screening and epidemiological surveillance. Brazil is the South American country with the highest HTLV-1 prevalence [2,3,4]. HTLV-1 infection is characterized by a chronic course and is associated with severe clinical manifestations, such as adult T-cell leukemia/lymphoma (ATL) and HTLV-1-associated myelopathy/tropical spastic paraparesis (HAM/TSP), as well as inflammatory conditions such as alveolitis, polymyositis, arthritis, and uveitis [5,6]. Following infection, viral RNA is converted into double-stranded DNA by the enzyme reverse transcriptase, and the resulting proviral DNA is integrated into the host cell genome, preferentially in CD4+ T lymphocytes [7,8,9]. Quantification of HTLV-1 proviral load (PVL) is an important biomarker associated with the risk of development and the rate of progression of ATL and HAM/TSP [10,11,12,13]. Despite its clinical relevance, PVL quantification methods still require standardization, and the wide variation in quantification methods limits methodological harmonization. Currently, there is substantial heterogeneity among real-time PCR (qPCR) protocols used across different centers. These variations include the choice of the appropriate biological matrix, which hinders protocol standardization and compromises comparability between studies [14,15,16,17]. One of the main obstacles for protocol standardization is the heterogeneity of normalization strategies and sample processing: many protocols use cellular fractions (buffy coat, peripheral blood mononuclear cells (PBMCs), or CD4+ cells), which introduce additional pre-analytical variability due to the handling of these materials [14,18]. Some protocols differ in how results are expressed, either as absolute concentration based on blood volume (copies/µL) or as PVL proportional to the number of cells (copies/1000 or 106 leukocytes or lymphocytes), requiring normalization based on a reference gene (albumin) [16]. Other protocols also report normalization based on total leukocyte counts, highlighting the broad methodological diversity currently in use [19]. Implementing suitable methodologies for PVL quantification remains challenging in laboratory settings, making it essential to validate strategies that combine high accuracy, reproducibility, and operational feasibility. We proposed that a simplified whole blood-based approach, developed in our laboratory, could be a suitable alternative to established volumetric and cell-normalized methods for HTLV-1 PVL quantification. This study evaluated whole blood volume-based absolute quantification (WBV copies/µL of blood), based on the direct conversion of Ct values through a standard curve independent of hematological parameters or reference genes, in comparison with established volumetric and cellular protocols. 2. Materials and Methods 2.1. Study Design This is a cross-sectional study conducted at the Complexo Hospitalar Universitário Professor Edgard Santos (COM-HUPES), a university hospital and referral center for the care of individuals with HTLV infection, located in Salvador, Bahia, Brazil. The study included a convenience sample of 53 participants over 18 years of age with HTLV-1 infection who were followed at COM-HUPES. Participants were included regardless of antiretroviral therapy exposure status, since the primary objective of this study was to compare qPCR quantification methodologies rather than evaluate biological determinants of proviral load variation. Therefore, all biological samples obtained from each participant were analyzed using all quantification approaches, enabling direct paired comparisons between methods. 2.2. Ethical Aspects This study is part of a research project that evaluated the effectiveness of antiretroviral therapy for the treatment of HTLV-1 infection, approved by the Research Ethics Committee of the Climério de Oliveira Maternity (UFBA), number 4,643,372. All participants provided written informed consent. 2.3. Sample Processing Blood samples were collected to measure HTLV-1 PVL in whole blood, buffy coat, PBMCs, and CD4+ cells. After collection, 1 mL aliquots of whole blood were prepared and distributed into cryovials. Complete blood count was performed for all samples. For buffy coat isolation, samples in EDTA tubes were centrifuged at 2000× g for 10 min, followed by aspiration of the leukocyte layer, which was transferred into cryovials. All aliquots were stored in freezers at −80 °C. PBMCs were isolated from whole-blood samples using a Ficoll-Paque density gradient (1.077 g/mL) [20]. After two washing steps with 1× PBS, the cells were resuspended in 1 mL of fetal bovine serum containing 10% dimethyl sulfoxide (DMSO) and cryopreserved at −80 °C. CD4+ T-cell isolation was performed by negative selection directly from whole blood using the EasySep™ Direct Human CD4+ T Cell Isolation Kit (Stemcell Technologies, Seattle, WA, USA) in conjunction with the EasySep™ Magnet (Stemcell Technologies, Seattle, WA, USA). According to the manufacturer’s specifications, fresh samples collected in heparin tubes were used and processed immediately after collection to ensure cellular integrity. Initially, 1.5 mL of whole blood was transferred to a 5 mL polystyrene tube, to which 75 µL of Isolation Cocktail and 75 µL of RapidSpheres™ (STEMCELL Technologies Inc., Vancouver, BC, Canada) were added. After a 5 min incubation at room temperature, the volume was adjusted to 2.5 mL with 1× PBS. The tube was placed in the magnet for 5 min to immobilize unwanted cells, while the supernatant containing enriched CD4+ T cells was carefully transferred to a new tube for an additional washing step. The isolated cells were then centrifuged at 200× g for 10 min; the supernatant was discarded, and the resulting cell pellet was immediately stored at −80 °C for subsequent DNA extraction. 2.4. Sample Thawing Whole blood, buffy coat, and CD4+ cell aliquots were thawed at room temperature (20–25 °C). For resuspension of the CD4+ cell pellet, 200 µL of 1× PBS was added to an Eppendorf tube, followed by the extraction step. For thawing of the peripheral blood mononuclear cells (PBMCs), an optimized protocol was used to remove DMSO and preserve cell viability. The cryovial containing the sample and RPMI medium were prewarmed in a 37 °C water bath. Subsequently, RPMI was added to the cell suspension (at a 1:1 ratio). The mixture was transferred to a Falcon-type tube containing 8 mL of RPMI supplemented with 10% fetal bovine serum (FBS) and centrifuged at 2000× g for 10 min. The supernatant was discarded, and the resulting pellet was resuspended in 600 µL of 1× PBS, for DNA extraction. 2.5. Nucleic Acid Extraction Genomic DNA extraction was performed in batches, under the same experimental conditions, using the PureLink™ Genomic DNA Mini Kit (Invitrogen, Carlsbad, CA, USA). The protocol was executed according to the manufacturer’s instructions. For each extraction, an initial volume of 200 µL of each sample was used, resulting in a final elution volume of 50 µL. The eluates were immediately stored in a freezer at −80 °C for further analysis. 2.6. qPCR Protocol Proviral load determination was performed by qPCR, based on the protocol previously developed and published by Tamegão-Lopes et al. [19]. We used the TaqMan® system on the CFX96™ Real-Time PCR Detection System (Bio-Rad Laboratories, Hercules, CA, USA), with the following cycling conditions: 2 min at 94 °C, followed by 45 cycles of 20 s at 94 °C and 40 s at 60 °C. The assay was designed to amplify two targets: a region of the HTLV-1 pol gene and the human albumin (ALB) gene as an endogenous control (reference gene). The primers and probes were designed and synthesized by Thermo Fisher Scientific (Waltham, MA, USA) using previously published sequences (Table 1). In this study, six different methodological approaches were used to quantify HTLV-1 proviral load (PVL). In addition to the molecular assay, calculation and normalization strategies were compared according to the following metrics: (I) WBV (copies/µL of blood), a protocol developed and standardized in our laboratory; (II) the quantification proposed by Tamegão-Lopes (QTL); (III) PVL normalized per 1000 leukocytes, applied to whole blood (WHL copies/10−3 cells), buffy coat, and PBMC fractions (PBMC copies/10−3 cells); and (IV) PVL per 1000 lymphocytes, using isolated CD4+ cells (CD4+ copies/10−3 cells). Although all methods were based on the same molecular assay, they differed in the normalization denominator used and the biological matrix analyzed. 2.7. Standard Curve Standard curves were established for both HTLV-1 and ALB targets for PVL quantification and normalization. The curves were generated from serial dilutions of purified and previously quantified amplicons, ranging from 10−1 to 10−14. After evaluating linearity, the dynamic range used to construct the standard curve was defined between 10−3 and 10−10, corresponding to the range with the best linear performance and amplification stability [14,21,22]. The initial concentration of genetic material was determined by fluorometry using the Qubit™ system with the HS DNA kit (Invitrogen, Carlsbad, CA, USA), for copy number calculation based on the molecular mass of the amplicons. Assay performance was initially validated using purified amplicons quantified by fluorometry, ensuring linearity and amplification efficiency prior to clinical sample analysis. A detailed validation of the standard curve, including inhibition assessment, exclusion of the stochastic limit, and the regression parameters, is described in Appendix B. The HTLV-1 standard curve showed an efficiency of 94.5%, with a coefficient of determination (R2) of 0.99, slope of −3.46, and a limit of detection of 6 copies/µL. For the albumin (ALB) gene, an efficiency of 97.6%, R2 of 0.99, slope of −3.38, and a limit of detection of 9 copies/µL were obtained. These parameters fall within the recommended criteria for real-time PCR assays, according to MIQE guidelines [23]. Standard curve reactions were performed in duplicate to ensure quantification accuracy. Clinical samples were analyzed in singlet, consistent with the study’s objective of comparing different methodological approaches under standardized experimental conditions, applied equally to all samples. Analytical quality was monitored through standard curve efficiency and amplification performance of the endogenous gene (ALB). A correction factor was established to ensure result reliability and compensate for systematic variations associated with the extraction process. Six samples were initially extracted; subsequently, 20 µL of each eluate was diluted in 180 µL of saline solution (0.9% NaCl) to simulate a diluted matrix, prior to a new extraction step. qPCR analysis showed a mean difference of ΔCt = 2.01 between the original and re-extracted eluates. Considering the exponential nature of qPCR, this difference corresponds to approximately a four-fold variation in copy number estimation. This ΔCt value was incorporated as a correction factor in the final equations for all HTLV-1 PVL calculations and was added to the Ct values obtained from clinical samples prior to conversion into copy numbers. The application of this correction factor was standardized to reduce variability associated with the extraction process. Sensitivity analyses using different correction-factor scenarios were additionally performed to evaluate the robustness of the proposed quantification approach (Appendix B). 2.8. Determination of Proviral Load WBV (copies/µL of blood) was determined through amplification of the specific target (HTLV-1), independently of normalization by an endogenous control (ALB). The main analytical tool was the previously established reference standard curve, which enabled the definition of a linear relationship between fluorescence and DNA quantity. 〖PVL = 10〗^((a × (Ct + CF) + b) (1) Equation (1) was used to convert Ct values into copy numbers, where “a” represents the slope of the curve, “CF” the correction factor obtained, and “b” the intercept. Final values were expressed as HTLV-1 copies/µL. The determination of PVL proposed by Tamegão-Lopes, et al. [19]. is initially based on a ratio derived from the quantitative relationship between the Ct of the target (HTLV-1) and the endogenous control (ALB). Subsequently, these values were multiplied by the patient’s total leukocyte count and by a factor of “2,” corresponding to the diploid nature of the cellular genome. The PVL results were expressed as HTLV-1 copies/mm3.(PVL = 2^(−Ct HTLV1)/2^(−CT Albumin) × Leukocytes × 2(2)Equation (2) is the final calculation proposed by Tamegão-Lopes et al. [19]. The measurement of PVL normalized by cell count (copies/1000 cells) was also evaluated [24]. These protocols estimate the proportion of HTLV-1 copies per 1000 leukocytes (whole blood, buffy coat, and PBMCs) or per CD4+ lymphocytes. To determine the ratio between the number of HTLV-1 copies and the number of cells, the calculation is based on quantification of the albumin gene, with the number of copies of this gene divided by two to represent the cellular genomic equivalent [25,26]. The absolute copy numbers of the HTLV-1 and albumin (ALB) gene were determined using the standard curve.(PVL = ((HTLV1 Copies))/(((ALB Copies)⁄2)) × 1000)(3)Equation (3) was the final equation used to determine PVL per 1000 cells. 2.9. Handling of Missing Data Samples were included in each analysis according to the availability and quality of biological material for the corresponding qPCR assay. Buffy coat samples were incorporated after the initial phase of sample collection and were therefore unavailable for a subset of participants. Additional missing data were related to unsuccessful CD4+ cell isolation, insufficient sample volume, or absence of HTLV-1 amplification in the analyzed specimens. No exclusions were made based on proviral load levels or predefined cell-count thresholds; all analyses were conducted using the available paired samples for each methodological comparison. Figure 1 shows the sample selection and progression flow. 2.10. Statistical Analysis PVL variables were log10-transformed and analyzed to assess association and agreement between measurements. Means were compared using the paired Student’s t-test, and linear association between the variables was evaluated using Pearson’s correlation coefficient (r). Agreement between the measurements was assessed by Bland–Altman analysis [27], through estimation of the mean difference (bias) and the 95% limits of agreement, as well as the concordance correlation coefficient (CCC) [28]. A p-value < 0.05 was considered statistically significant. Statistical analyses were performed using Jamovi software, version 2.3. 3. Results The comparison was structured in three sequential steps. First, whole blood volume-based absolute quantification was compared with the protocol proposed by Tamegão-Lopes et al. [19]. to validate the accuracy of our approach for quantifying proviral load in copies per microliter (µL). Subsequently, the analysis was focused on protocols normalized per 1000 cells (leukocytes and lymphocytes) across different biological matrices: whole blood, buffy coat, PBMCs, and CD4+ cells. For this comparison, the protocol using isolated CD4+ cells was adopted as the biological reference, considering the preferential tropism of HTLV-1 for CD4+ T lymphocytes, which represent the main in vivo proviral reservoir. Finally, WBV (copies/µL of blood) was compared with the protocols normalized per 1000 cells to evaluate potential interchangeability between the methods. 3.1. Demographic and Clinical Profile Study participants had a mean age of 56.3 ± 9.3 years, with a predominance of females (80.3%). Most individuals were symptomatic (75.9%). 3.2. Validation of Volume-Based Quantification (copies/µL) Table 2 presents all comparative analyses between the methods for quantifying proviral load by blood volume (copies/µL), comparing the performance of the quantification with the protocol proposed by Tamegão-Lopes, et al. [19]. Comparison of the means using the paired t-test showed statistically significant differences between WBV (copies/µL of blood) and QTL (p < 0.001), although with similar average values. WBV (copies/µL of blood) showed a lower mean (1.73 ± 0.72 log10) compared to the QTL protocol (2.00 ± 0.75 log10). The Pearson correlation analysis between the quantification strategies revealed strong and significant positive associations for all comparisons (Table 2; p < 0.001). The correlation between WBV (copies/µL of blood) and the QTL method reached the highest correlation coefficient (r = 0.93). Figure 2 shows the positive linearity between these two protocols and confirms the technical robustness of the two blood volume-based quantification methods. The concordance analyses reinforced the clinical applicability of WBV (copies/µL of blood), which showed the highest concordance correlation coefficient (CCC = 0.866) with the QTL protocol (Table 2). The Bland–Altman plot for this comparison (Figure 3) revealed a mean bias of −0.273 log10, indicating a slight underestimation, but with narrow limits of agreement (−0.822 and 0.276) and points evenly distributed around the mean, with minimal systematic difference between the blood volume-based quantification methods. Correlation and concordance metrics remained largely stable across sensitivity scenarios, whereas Bland–Altman bias varied according to the correction-factor magnitude (Appendix B). 3.3. Validation of Biological Matrices Based on Protocols Normalized per 1000 Cells The analysis focused on protocols normalized per 1000 cells, using the isolated CD4+ compartment as the biological reference. Comparison of the means revealed that the CD4+ compartment consistently exhibited higher HTLV-1 PVL than all other matrices analyzed (Figure 4). The largest statistical differences were observed between CD4+ and WHL (p < 0.001) and CD4+ and buffy coat (p < 0.001), whereas the closest agreement was observed with PBMC copies/10−3 cells (p < 0.001) (Table 3). Despite differences in mean PVL due to the cellular heterogeneity of each matrix, Pearson correlation analyses between the protocols normalized per 1000 cells revealed strong and statistically significant positive associations with the target cell compartment (CD4+) (Table 4). The highest correlation coefficient was observed between CD4+ and PBMCs (r = 0.83). Figure 5 illustrates this linear association between both methods normalized per 1000 cells. Although the CD4+ compartment showed the highest viral density, variations in proviral load in the other biological matrices tested (whole blood, buffy coat, and PBMCs) followed the variations observed in the biological reference. Among the protocols normalized per 1000 cells, the protocol reporting HTLV-1 copies per 1000 lymphocytes (CD4) showed the highest concordance with PBMCs (CCC = 0.782). In contrast, WHL and buffy coat exhibited the lowest concordance (CCC = 0.520 and 0.555, respectively), with positive biases exceeding 0.500 log10 (Table 5). The corresponding Bland–Altman plots illustrate that most WHL and buffy coat samples lie above the zero line, indicating a tendency to underestimate proviral load when compared to the main target cell compartment (CD4+), due to the heterogeneity of the cellular population (Figure 6). 3.4. Interchangeability Between Methods The analysis of interchangeability between protocols was used to evaluate WBV (copies/µL of blood) in comparison to the CD4+-based protocol, normalized per 1000 cells. The paired t-test indicated a statistically significant difference between the mean values (p < 0.031) (Table 6), and Figure 7 showed overlapping confidence intervals between the two methods. This proximity is reflected by a strong positive correlation (r = 0.84; p < 0.001) (Table 6). The clear linearity shown in Figure 8 confirms the robustness of volumetric quantification in reflecting the proviral load of the target cell compartment. Methodological robustness was further reinforced by the concordance analyses. The comparison between WBV (copies/µL of blood) and CD4+ showed a CCC of 0.811, surpassing the concordance observed for WHL (copies/10−3 cells) and buffy coat matrices when normalized per 1000 cells (Table 6). Bland–Altman analysis revealed the lowest systematic bias between the protocols, with a mean bias of 0.115 log10, narrow limits of agreement, and uniform distribution (Figure 9). These findings underscore the analytical precision and clinical feasibility of WBV (copies/µL of blood) as a viable and robust alternative to cell normalization-dependent protocols. Deming regression analysis was used to evaluate the interchangeability between the WBV (copies/µL of blood) protocol and the protocol normalized per 1000 lymphocytes based on isolated CD4+ cells (Table 7), assuming a ratio of measurement error variances (λ) equal to 1. The scatter plot distribution showed good agreement between the methods (Figure 10). We observed an intercept of 0.197 (95% CI: −0.082 to 0.476) and a slope of 0.820 (95% CI: 0.664 to 0.975) in the comparison between WBV (copies/µL of blood) and the CD4+ compartment. The inclusion of zero within the intercept confidence interval indicates the absence of a constant systematic error between the methods. The absence of 1.0 in the confidence interval suggests the presence of a slight proportional systematic difference, where WBV (copies/µL of blood) tends to yield slightly different values at higher proviral load ranges compared to CD4+ isolation. 4. Discussion The findings of this study demonstrate a strong linear correlation and high concordance (CCC = 0.866) between whole blood volume-based absolute quantification (copies/µL) and the protocol proposed by Tamegão, et al. [19]. (r = 0.93). These results indicate a robust comparability between methods that express measurements using total blood volume as a denominator. The strong statistical association validates the precision of our protocol in producing consistent results when compared to previously described and validated protocols in the literature. Such findings support monitoring PVL by absolute volume as a reliable and reproducible analytical strategy. The stability of this correlation demonstrates that WBV (copies/µL of blood) is a robust methodology comparable to current standard volumetric methods. The systematic difference observed between the QTL protocol and WBV (copies/µL of blood) (mean bias of −0.273 log10) may be related to the mathematical structure of the calculation used. Unlike our methodology, which uses the actual blood volume (µL) as a direct denominator, the QTL protocol is based on the relative ratio between the viral target and the endogenous gene (ALB), multiplied by the total leukocyte count and corrected by a cellular diploidy factor. This model incorporates multiple variables that can influence the final estimated value, including the relative efficiency of qPCR assays and the accuracy of hematological counts. Since each of these terms is multiplicative, small variations in any component can amplify the final estimated PVL. In contrast, the volumetric model of WBV (copies/µL of blood) reduces the number of intermediate steps and eliminates dependence on external hematological parameters. Systematic discrepancies observed among the protocols normalized per 1000 cells become evident when compared to the isolated CD4+ compartment. The WHL (copies/10−3 cells) and buffy coat matrices based on protocols normalized per 1000 leukocytes exhibited the largest systematic biases (0.527 and 0.531 log10, respectively), which can be explained by the high cellular population heterogeneity in these matrices. As the quantification of albumin gene copies occurs in all nucleated cells [25,29], the presence of cells that do not harbor the HTLV-1 provirus, such as granulocytes, creates a mathematical dilution effect caused by the cellular composition that affects the ratio of HTLV-1 copies to albumin copies. This is because T lymphocytes are the predominant cells infected by HTLV-1 [30,31,32,33], making leukocyte-based normalization less precise in these complex matrices. In contrast, differences relative to PBMCs (0.211 log10), which showed the highest concordance observed among matrices compared to CD4+ (CCC = 0.782), reflect the close similarity between that cell fraction and the lymphocyte compartment. The strong concordance between WBV (copies/µL) and CD4+ normalized per 1000 lymphocytes (CCC = 0.811), combined with the low systematic bias, indicates comparable performance between the approaches. This interchangeability is further supported by Deming regression analysis, which showed no constant systematic error (Intercept: 0.197; 95% CI: −0.082 to 0.476). However, the slope below unity (0.820; 95% CI: 0.664 to 0.975) indicates a proportional error, revealing that the relative differences between methods increase at higher proviral load ranges. Nevertheless, the magnitude of this discrepancy is limited and may not affect the performance of the WBV (copies/µL of blood) protocol for clinical application. These findings indicate that WBV (copies/µL) represents a consistent alternative to the CD4+-based protocol. The use of whole blood has the advantage of eliminating complex pre-analytical steps that can introduce additional errors and increase the operational cost to the diagnosis for clinical monitoring. From a laboratory and large-scale implementation perspective, WBV (copies/µL of blood) offers significant operational advantages. The volumetric method relies exclusively on quantification of the viral target (HTLV-1), eliminating the need for a reference gene (albumin) as the calculation denominator. This simplification reduces the number of reactions required per sample and decreases the consumption of primers, probes, and qPCR reagents, while also optimizing the assay execution time. The use of a previously established standard curve on a routine thermocycler allows direct conversion of Ct values into the absolute number of copies per µL of total blood, maintaining analytical traceability without reliance on additional hematological parameters. In addition, WBV (copies/µL of blood) does not require global leukocyte counts obtained from a complete blood count. This optimizes the pre-analytical phase, as only a single tube is needed for blood collection. This feature is particularly relevant in molecular biology laboratories that do not have their own hematology analyzers, reducing fragmentation in the analytical workflow and potentially increasing process standardization and result traceability. Using total blood as the primary matrix also provides a logistical advantage over other protocols normalized per 1000 cells, which require cell fractionation (buffy coat, PBMCs, and isolated CD4+), additional processing steps, and greater technical infrastructure. Reducing these pre-analytical steps can contribute to lower technical variability and greater feasibility for implementation in routine clinical settings and epidemiological surveillance. The small sample size is a limitation of our study. Nevertheless, it allowed a robust comparative analysis between the different protocols evaluated. From a technical standpoint, the effectiveness of WBV (copies/µL of blood) depends on a standard curve with high precision, requiring efficiencies close to 100% and minimal variation among serial dilutions—essential characteristics of well-standardized qPCR assays. The pre-analytical phase was conducted under strict standardization to minimize potential sources of variation between different samples and biological matrices. Isolation of CD4+ cells, PBMC processing, and buffy coat preparation require specialized training to reduce inter-sample variability. Finally, the simultaneous processing of four matrices per patient constituted a methodological strength of the study, ensuring direct comparability between protocols, as all PVL comparisons were performed under the same temporal and analytical conditions. 5. Conclusions Whole blood volume-based absolute quantification (copies/µL of blood) is a precise, reproducible, and operationally advantageous tool for determining HTLV-1 PVL. The method showed high concordance with the CD4+-based protocol, overcoming the limitations observed in leukocyte-normalized protocols (whole blood and buffy coat), which are more susceptible to interference from cellular heterogeneity. WBV (copies/µL of blood) eliminates dependence on external hematological parameters and simplifies the laboratory workflow, reducing costs and processing time. Therefore, this protocol represents a reliable and feasible alternative for large-scale clinical monitoring, facilitating access to high-precision molecular surveillance across diverse public health settings.